CodeBreak-lg.png

Amgen Oncology is testing a study drug called sotorasib to determine whether it has the potential to help people whose cancer contains the KRAS G12C mutation.

Click below to find CodeBreaK clinical trials and learn more about sotorasib and the KRAS G12C mutation.

Explore CodeBreaK Clinical Trials

If you don’t know whether your cancer has the KRAS G12C mutation, ask your doctor if your cancer has been tested for genetic mutations. You can also contact Amgen for more information.

codebreak-image

A clinical trial for patients with advanced solid tumors that have the KRAS G12C mutation

Status
Recruiting

PHASE

Phase 1/2

CONDITION

Advanced solid tumors

STUDY DRUGS

sotorasib alone or combined with another anti-cancer therapy

codebreak-image

A clinical trial for patients with advanced solid tumors that have the KRAS G12C mutation

Status
Recruiting

PHASE

Phase 1b/2

CONDITION

Advanced solid tumors

STUDY DRUGS

sotorasib and other anti-cancer therapies

If you are a physician or another healthcare professional interested in learning more about a CodeBreaK trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.